Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details)

v3.20.2
Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares
Sep. 30, 2020
Feb. 12, 2020
Dec. 31, 2019
Nov. 30, 2019
Sep. 30, 2019
Anti-dilutive securities          
Warrant issued to purchase common stock 2,118,094       2,118,344
Preferred stock, shares outstanding 0   0    
Convertible Preferred Stock          
Anti-dilutive securities          
Preferred stock, shares outstanding 0     666  
Convertible Preferred Stock | Common Stock          
Anti-dilutive securities          
Conversion preferred stock into common stock       666,000  
Loan Agreement          
Anti-dilutive securities          
Warrant issued to purchase common stock   27,548